A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
It is estimated that up to 45% of patients with depression do not have an adequate response to a first trial of antidepressant therapy with even higher reported rates for the elderly patients. To compare the efficacy and the tolerability of venlafaxine vs. paroxetine in elderly patients suffering from resistant major depression, who did not respond to at least two previous adequate trials of antidepressants. Patients entered an 8-week single-blind study. Patients were rated using the Clinical Global Impression Scale, Hamilton Rating Scale for Depression, and the Geriatric Depression Scale. Assessments were performed at baseline and on days 7, 14, 21, 28, 42 and 56. Side effects were recorded in a systemic manner. Thirty patients were included in the study, (17 women, 13 men; mean age=75.9 years, range: 68-83) and all had completed the 6-week trial. Mean dose of venlafaxine used was 165 mg/day (SD=73.8; range 75-300 mg). Mean dose of paroxetine used was 26 mg/day (SD=15.04; range 10-60 mg). Nine patients treated with venlafaxine (60%) and five patients treated with paroxetine (33%) remitted after 8 weeks of treatment. Four patients treated with venlafaxine and eight patients treated with paroxetine failed to respond. Significant improvement in Hamilton Rating Scale for Depression scores between baseline and endpoint were observed in both groups of patients. The mean Hamilton Rating Scale for Depression change for paroxetine was -12.5 and for venlafaxine -19.1 (P<0.05). The mean Geriatric Depression Scale change for paroxetine was -3.2 and for venlafaxine -6.0 (P<0.3). The mean Clinical Global Impression Scale change was -2.3 for paroxetine and -3.5 for venlafaxine (P<0.05). Venlafaxine was significantly superior to paroxetine on Clinical Global Impression Scale and Hamilton Rating Scale for Depression measures. Side effects were transient and did not differ between treatment groups. Elderly depressed patients resistant to previous treatments had responded to a trial of paroxetine or venlafaxine. Remission rates were higher for venlafaxine and tolerability was acceptable for both compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 4×
“Paroxetine was selected as the comparator drug because it is one of the most frequently prescribed selective seratonin reuptake inhibitors (SSRIs) worldwide (Nemeroff, 1993).”
BackgroundInfluentialDEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison
Poirier, M.-F., & Boyer, P. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.12 · Cited by 185 · cited 2×
“These results are in line with the previously cited studies that compared the efficacy of both drugs in treatment-resistant younger patients (Poirier and Boyer, 1999a).”
BackgroundResultInfluentialDieric, M., Ravizza, U., Realini, R., & Martin, A. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00292-8 · Cited by 152
Cited by
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“…three randomized studies including one placebocontrolled trial (one open, Kok et al. 2007: lithium augmentation vs. phenelzine; one single-blind, Mazeh et al. 2007: venlafaxine vs. paroxetine; one double-blind, Sunderland et al. 1994: selegiline vs. placebo) and 10 open-label uncontrolled…”
BackgroundA Systematic Review of Treatments for Refractory Depression in Older People
Cooper, C., Katona, C., Lyketsos, K., Blazer, D., Brodaty, H., Rabins, P., de Mendonça Lima, C. A., & Livingston, G. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081165 · Cited by 176
Cristancho, P., Lenard, E., Lenze, E. J., Miller, J. P., Brown, P. J., Roose, S. P., Montes-Garcia, C., Blumberger, D. M., Mulsant, B. H., Lavretsky, H., et al. (2019) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.04.005 · Cited by 54
Baba, H., Kito, S., Nukariya, K., Takeshima, M., Fujise, N., Iga, J., Oshibuchi, H., Kawano, M., Kimura, M., Mizukami, K., et al. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13349 · Cited by 50
Metadata
- Authors
- Mazeh, D., Shahal, B., Aviv, A., Zemishlani, H., & Barak, Y.
- Venue
- International Clinical Psychopharmacology
- Published
- 2007-11
- Volume
- 22
- Issue
- 6
- Pages
- 371-375
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2036346162
- Cited by
- 32
- References
- 4
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. https://app.cochat.ai/papers/10.1097/yic.0b013e32817396ae
- The paper
- Mazeh, D., Shahal, B., Aviv, A., Zemishlani, H., & Barak, Y. (2007). A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e32817396ae
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.